Abstract
Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Current Drug Safety
Title: Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Volume: 5 Issue: 4
Author(s): Matthew P. Baker and Francis J. Carr
Affiliation:
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Abstract: Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Export Options
About this article
Cite this article as:
Baker P. Matthew and Carr J. Francis, Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792246000
DOI https://dx.doi.org/10.2174/157488610792246000 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Anti-NMDA Receptor Encephalitis in a Patient with a History of Autism Spectrum Disorder
Adolescent Psychiatry Evasion of Host Immunity by Virulent Salmonella: Implications for Vaccine Design
Current Medicinal Chemistry Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets The Impact of the Parent-Physician Relationship on Parental Vaccine Safety Perceptions
Current Drug Safety Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research A179L, a New Viral Bcl2 Homolog Targeting Beclin 1 Autophagy Related Protein
Current Molecular Medicine Selection and Evaluation of the Pediatric Epilepsy Surgical Candidates
Current Pediatric Reviews Self-Organizing Maps for the Classification of Gallic Acylate Polyphenols as HSV-1 Inhibitors
Medicinal Chemistry Infectious Causes of Childhood Disability
Infectious Disorders - Drug Targets Vaccine Ingredients: Components that Influence Vaccine Efficacy
Mini-Reviews in Medicinal Chemistry Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design Behcets Syndrome: Literature Review
Current Rheumatology Reviews The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry